BAUSCH HEALTH COS INC (BHC) Stock Price, Forecast & Analysis
NYSE:BHC • CA0717341071
BHC Key Statistics, Chart & Performance
The current stock price of BHC is 6.005 USD. In the past month the price increased by 3.79%. In the past year, price decreased by -19.09%.
BHC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BHC. When comparing the yearly performance of all stocks, BHC is a bad performer in the overall market: 79.72% of all stocks are doing better.
BHC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BHC. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
BHC Financial Highlights
Over the last trailing twelve months BHC reported a non-GAAP Earnings per Share(EPS) of 3.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.53% | ||
| ROA | 0.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BHC Forecast & Estimates
9 analysts have analysed BHC and the average price target is 7.43 USD. This implies a price increase of 23.72% is expected in the next year compared to the current price of 6.005.
For the next year, analysts expect an EPS growth of 13.77% and a revenue growth 4.23% for BHC
BHC Ownership
BHC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.79 | 985.228B | ||
| JNJ | JOHNSON & JOHNSON | 20.98 | 593.362B | ||
| MRK | MERCK & CO. INC. | 22.65 | 307.597B | ||
| PFE | PFIZER INC | 8.98 | 154.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.02 | 125.402B | ||
| ZTS | ZOETIS INC | 18.51 | 56.699B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.72 | 26.207B | ||
| VTRS | VIATRIS INC | 6.34 | 18.503B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 26.1 | 13.107B | ||
| AXSM | AXSOME THERAPEUTICS INC | 201.83 | 8.567B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BHC
Company Profile
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Company Info
BAUSCH HEALTH COS INC
2150 St. Elzear Blvd. West
Laval QUEBEC H7L 4A8 CA
CEO: Joseph C. Papa
Employees: 20700
Phone: 18003611448
BAUSCH HEALTH COS INC / BHC FAQ
What does BAUSCH HEALTH COS INC do?
Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Can you provide the latest stock price for BAUSCH HEALTH COS INC?
The current stock price of BHC is 6.005 USD. The price decreased by -0.25% in the last trading session.
What is the dividend status of BAUSCH HEALTH COS INC?
BHC does not pay a dividend.
How is the ChartMill rating for BAUSCH HEALTH COS INC?
BHC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is BHC stock listed?
BHC stock is listed on the New York Stock Exchange exchange.
What sector and industry does BAUSCH HEALTH COS INC belong to?
BAUSCH HEALTH COS INC (BHC) operates in the Health Care sector and the Pharmaceuticals industry.